PainChek Lands First Real Contracts Inside Sabra’s 20,000-Bed US Network
PainChek converts Sabra agreement into real contracts
PainChek Limited (ASX: PCK) has secured its first two commercial contracts under the Master Services Agreement (MSA) signed with Sabra Health Care REIT in April 2026. The two contracts are both three-year deployments at ‘Traditions’ memory care facilities in the US, targeting the skilled nursing sector where high populations of people living with dementia reside.
While the financial value of these agreements is not considered material, they represent the first tangible commercial proof-point of the Sabra strategy, confirming that the relationship is converting from agreement to active deployment. The broader Sabra network spans 329 facilities and up to 20,000 beds.
When big ASX news breaks, our subscribers know first
What the Sabra agreement means for PainChek’s US strategy
A capital-light blueprint for the US market
The commercial model underpinning the Sabra relationship is structured so that Sabra funds the cost of PainChek’s solution on behalf of its operating partners, removing adoption barriers at the operator level. PainChek has described this as a “capital-light go-to-market mechanism,” and management has noted the model is “transferrable to other major US-based real estate investment trusts who own large numbers of long-term care and senior living facilities.”
Sabra fast facts:
- Market capitalisation: approximately $5 billion
- Bed and unit count: more than 36,000 across the US and Canada
- Facility types: skilled nursing, long-term care, senior housing, and behavioural health
- Geography: United States and Canada
- Classification: one of the larger specialised healthcare real estate investment trusts (REITs) in North America
The addressable problem: pain and dementia in US aged care
The US skilled nursing and memory care sector presents a structurally significant market opportunity for PainChek. More than 3 million US nursing home residents are currently diagnosed with Alzheimer’s disease and related dementias (ADRD), a group for whom pain assessment and pain management is described as a “daily struggle.”
PainChek is the only FDA cleared medical device to assess pain specifically for people living with dementia, positioning it as a category-defining solution in a chronically underserved segment of aged care. The scale of the unmet need, combined with the absence of comparable cleared alternatives, makes the US skilled nursing sector a high-priority market for the company’s commercial expansion.
CEO Philip Daffas
“We are delighted to see the rapid uptake and significant growing interest from the US skilled nursing and memory care sector, which is where PainChek can provide the greatest impact. Today, more than three million US nursing home residents are currently diagnosed with Alzheimer’s disease and related dementias (ADRD) and for whom pain assessment and pain management is a daily struggle. PainChek is the only FDA cleared medical device to assess pain for people living with dementia. The Sabra agreement facilitates the accelerated uptake of PainChek across Sabra’s 20,000 bed network of long-term care and senior housing facilities. This model is also a blueprint for PainChek in the US and transferrable to other major US-based real estate investment trusts who own large numbers of long-term care and senior living facilities.”
The next major ASX story will hit our subscribers first
Expanding the pipeline: what comes next
PainChek is actively negotiating with additional Sabra Health Group homes beyond the initial two ‘Traditions’ facilities, targeting the broader 20,000-bed network. The team is also engaging with another large US provider specialising in the memory care sector, though that provider has not been named publicly.
New opportunities have emerged directly from conference activity. At the Argentum conference in Nashville, Tennessee in May 2026, collaborators from the IOWA clinic presented PainChek’s FDA successful clinical trial outcomes to an audience of memory care and skilled nursing providers, generating inbound pipeline interest.
The key US pipeline priorities are:
- Expand deployments across the remaining Sabra Health Group homes, targeting the full 20,000-bed network
- Progress negotiations with the unnamed large US memory care provider
- Leverage FDA trial results presentations at sector conferences as a lead-generation mechanism
The Sabra relationship milestones to date are summarised below:
| Event | Date | Detail | Significance | Status |
|---|---|---|---|---|
| Master Services Agreement signed | 14 April 2026 | PainChek entered MSA with Sabra Health Care REIT (Nasdaq: SBRA) | Established framework for deployment across up to 20,000 beds in 329 facilities | Completed |
| Argentum Conference, Nashville | May 2026 | IOWA clinic collaborators presented PainChek FDA clinical trial outcomes | Generated pipeline interest from memory care and skilled nursing providers | Completed |
| First commercial contracts secured | 4 June 2026 | Two three-year contracts signed with ‘Traditions’ memory care facilities | First tangible conversion of MSA into active deployments | Completed |
| Expansion negotiations underway | Ongoing | Discussions with additional Sabra homes and a separate large US memory care provider | Pipeline broadening beyond initial two facilities | In progress |
PainChek at a glance: global credentials supporting the US push
PainChek’s US market entry is built on a proven global platform, not a standing start. Key credentials include:
- Regulatory clearance in 9 markets: Australia, USA, Canada, EU, New Zealand, Singapore, Malaysia, and the United Kingdom
- Contracts with more than 2,000 aged care facilities globally
- More than 20,000,000 digital pain assessments conducted to date
- Trusted by thousands of nurses, carers, and clinicians worldwide
Don’t Miss the Next Healthcare Breakout on the ASX
Big News Blast delivers FREE breaking ASX healthcare news directly to your inbox within minutes of release, with in-depth analysis already done. Join 20,000+ subscribers who stay ahead of the market the moment announcements drop. Click the “Free Alerts” button at StockWire X to start receiving real-time alerts today.